nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—Stomatitis—Methotrexate—testicular cancer	0.00093	0.00093	CcSEcCtD
Ibandronate—Asthma—Doxorubicin—testicular cancer	0.000926	0.000926	CcSEcCtD
Ibandronate—Influenza—Doxorubicin—testicular cancer	0.000926	0.000926	CcSEcCtD
Ibandronate—Dysphagia—Doxorubicin—testicular cancer	0.000926	0.000926	CcSEcCtD
Ibandronate—Asthenia—Ifosfamide—testicular cancer	0.000923	0.000923	CcSEcCtD
Ibandronate—Sweating—Methotrexate—testicular cancer	0.000915	0.000915	CcSEcCtD
Ibandronate—Feeling abnormal—Cisplatin—testicular cancer	0.000914	0.000914	CcSEcCtD
Ibandronate—Paraesthesia—Etoposide—testicular cancer	0.000912	0.000912	CcSEcCtD
Ibandronate—Pruritus—Ifosfamide—testicular cancer	0.00091	0.00091	CcSEcCtD
Ibandronate—Weight decreased—Epirubicin—testicular cancer	0.000906	0.000906	CcSEcCtD
Ibandronate—Hepatobiliary disease—Methotrexate—testicular cancer	0.000902	0.000902	CcSEcCtD
Ibandronate—Pneumonia—Epirubicin—testicular cancer	0.000898	0.000898	CcSEcCtD
Ibandronate—Nausea—Bleomycin—testicular cancer	0.000894	0.000894	CcSEcCtD
Ibandronate—Infestation—Epirubicin—testicular cancer	0.000893	0.000893	CcSEcCtD
Ibandronate—Infestation NOS—Epirubicin—testicular cancer	0.000893	0.000893	CcSEcCtD
Ibandronate—Vomiting—Dactinomycin—testicular cancer	0.000892	0.000892	CcSEcCtD
Ibandronate—Bronchitis—Doxorubicin—testicular cancer	0.000891	0.000891	CcSEcCtD
Ibandronate—Rash—Dactinomycin—testicular cancer	0.000885	0.000885	CcSEcCtD
Ibandronate—Decreased appetite—Etoposide—testicular cancer	0.000883	0.000883	CcSEcCtD
Ibandronate—Diarrhoea—Ifosfamide—testicular cancer	0.00088	0.00088	CcSEcCtD
Ibandronate—Renal failure—Epirubicin—testicular cancer	0.000878	0.000878	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Etoposide—testicular cancer	0.000877	0.000877	CcSEcCtD
Ibandronate—Body temperature increased—Cisplatin—testicular cancer	0.000876	0.000876	CcSEcCtD
Ibandronate—Fatigue—Etoposide—testicular cancer	0.000876	0.000876	CcSEcCtD
Ibandronate—Stomatitis—Epirubicin—testicular cancer	0.00087	0.00087	CcSEcCtD
Ibandronate—Pain—Etoposide—testicular cancer	0.000869	0.000869	CcSEcCtD
Ibandronate—Constipation—Etoposide—testicular cancer	0.000869	0.000869	CcSEcCtD
Ibandronate—Urinary tract infection—Epirubicin—testicular cancer	0.000868	0.000868	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000861	0.000861	CcSEcCtD
Ibandronate—Haemoglobin—Methotrexate—testicular cancer	0.000861	0.000861	CcSEcCtD
Ibandronate—Haemorrhage—Methotrexate—testicular cancer	0.000856	0.000856	CcSEcCtD
Ibandronate—Sweating—Epirubicin—testicular cancer	0.000856	0.000856	CcSEcCtD
Ibandronate—Dizziness—Ifosfamide—testicular cancer	0.00085	0.00085	CcSEcCtD
Ibandronate—Pharyngitis—Methotrexate—testicular cancer	0.00085	0.00085	CcSEcCtD
Ibandronate—Urinary tract disorder—Methotrexate—testicular cancer	0.000846	0.000846	CcSEcCtD
Ibandronate—Hepatobiliary disease—Epirubicin—testicular cancer	0.000844	0.000844	CcSEcCtD
Ibandronate—Urethral disorder—Methotrexate—testicular cancer	0.000839	0.000839	CcSEcCtD
Ibandronate—Weight decreased—Doxorubicin—testicular cancer	0.000838	0.000838	CcSEcCtD
Ibandronate—Feeling abnormal—Etoposide—testicular cancer	0.000837	0.000837	CcSEcCtD
Ibandronate—Nausea—Dactinomycin—testicular cancer	0.000834	0.000834	CcSEcCtD
Ibandronate—Pneumonia—Doxorubicin—testicular cancer	0.000831	0.000831	CcSEcCtD
Ibandronate—Gastrointestinal pain—Etoposide—testicular cancer	0.000831	0.000831	CcSEcCtD
Ibandronate—Infestation—Doxorubicin—testicular cancer	0.000826	0.000826	CcSEcCtD
Ibandronate—Infestation NOS—Doxorubicin—testicular cancer	0.000826	0.000826	CcSEcCtD
Ibandronate—Vomiting—Ifosfamide—testicular cancer	0.000818	0.000818	CcSEcCtD
Ibandronate—Hypersensitivity—Cisplatin—testicular cancer	0.000817	0.000817	CcSEcCtD
Ibandronate—Renal failure—Doxorubicin—testicular cancer	0.000812	0.000812	CcSEcCtD
Ibandronate—Rash—Ifosfamide—testicular cancer	0.000811	0.000811	CcSEcCtD
Ibandronate—Dermatitis—Ifosfamide—testicular cancer	0.00081	0.00081	CcSEcCtD
Ibandronate—Urticaria—Etoposide—testicular cancer	0.000807	0.000807	CcSEcCtD
Ibandronate—Haemoglobin—Epirubicin—testicular cancer	0.000805	0.000805	CcSEcCtD
Ibandronate—Stomatitis—Doxorubicin—testicular cancer	0.000805	0.000805	CcSEcCtD
Ibandronate—Body temperature increased—Etoposide—testicular cancer	0.000803	0.000803	CcSEcCtD
Ibandronate—Abdominal pain—Etoposide—testicular cancer	0.000803	0.000803	CcSEcCtD
Ibandronate—Urinary tract infection—Doxorubicin—testicular cancer	0.000803	0.000803	CcSEcCtD
Ibandronate—Haemorrhage—Epirubicin—testicular cancer	0.000801	0.000801	CcSEcCtD
Ibandronate—Eye disorder—Methotrexate—testicular cancer	0.0008	0.0008	CcSEcCtD
Ibandronate—Asthenia—Cisplatin—testicular cancer	0.000795	0.000795	CcSEcCtD
Ibandronate—Pharyngitis—Epirubicin—testicular cancer	0.000795	0.000795	CcSEcCtD
Ibandronate—Cardiac disorder—Methotrexate—testicular cancer	0.000795	0.000795	CcSEcCtD
Ibandronate—Sweating—Doxorubicin—testicular cancer	0.000792	0.000792	CcSEcCtD
Ibandronate—Urinary tract disorder—Epirubicin—testicular cancer	0.000791	0.000791	CcSEcCtD
Ibandronate—Oedema peripheral—Epirubicin—testicular cancer	0.000789	0.000789	CcSEcCtD
Ibandronate—Connective tissue disorder—Epirubicin—testicular cancer	0.000788	0.000788	CcSEcCtD
Ibandronate—Urethral disorder—Epirubicin—testicular cancer	0.000786	0.000786	CcSEcCtD
Ibandronate—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000781	0.000781	CcSEcCtD
Ibandronate—Angiopathy—Methotrexate—testicular cancer	0.000777	0.000777	CcSEcCtD
Ibandronate—Immune system disorder—Methotrexate—testicular cancer	0.000774	0.000774	CcSEcCtD
Ibandronate—Mediastinal disorder—Methotrexate—testicular cancer	0.000772	0.000772	CcSEcCtD
Ibandronate—Chills—Methotrexate—testicular cancer	0.000768	0.000768	CcSEcCtD
Ibandronate—Nausea—Ifosfamide—testicular cancer	0.000764	0.000764	CcSEcCtD
Ibandronate—Diarrhoea—Cisplatin—testicular cancer	0.000759	0.000759	CcSEcCtD
Ibandronate—Alopecia—Methotrexate—testicular cancer	0.000757	0.000757	CcSEcCtD
Ibandronate—Mental disorder—Methotrexate—testicular cancer	0.00075	0.00075	CcSEcCtD
Ibandronate—Eye disorder—Epirubicin—testicular cancer	0.000749	0.000749	CcSEcCtD
Ibandronate—Hypersensitivity—Etoposide—testicular cancer	0.000748	0.000748	CcSEcCtD
Ibandronate—Erythema—Methotrexate—testicular cancer	0.000745	0.000745	CcSEcCtD
Ibandronate—Malnutrition—Methotrexate—testicular cancer	0.000745	0.000745	CcSEcCtD
Ibandronate—Haemoglobin—Doxorubicin—testicular cancer	0.000745	0.000745	CcSEcCtD
Ibandronate—Cardiac disorder—Epirubicin—testicular cancer	0.000744	0.000744	CcSEcCtD
Ibandronate—Haemorrhage—Doxorubicin—testicular cancer	0.000742	0.000742	CcSEcCtD
Ibandronate—Pharyngitis—Doxorubicin—testicular cancer	0.000736	0.000736	CcSEcCtD
Ibandronate—Urinary tract disorder—Doxorubicin—testicular cancer	0.000732	0.000732	CcSEcCtD
Ibandronate—Oedema peripheral—Doxorubicin—testicular cancer	0.00073	0.00073	CcSEcCtD
Ibandronate—Dysgeusia—Methotrexate—testicular cancer	0.00073	0.00073	CcSEcCtD
Ibandronate—Asthenia—Etoposide—testicular cancer	0.000729	0.000729	CcSEcCtD
Ibandronate—Connective tissue disorder—Doxorubicin—testicular cancer	0.000729	0.000729	CcSEcCtD
Ibandronate—Angiopathy—Epirubicin—testicular cancer	0.000727	0.000727	CcSEcCtD
Ibandronate—Urethral disorder—Doxorubicin—testicular cancer	0.000727	0.000727	CcSEcCtD
Ibandronate—Immune system disorder—Epirubicin—testicular cancer	0.000724	0.000724	CcSEcCtD
Ibandronate—Mediastinal disorder—Epirubicin—testicular cancer	0.000722	0.000722	CcSEcCtD
Ibandronate—Back pain—Methotrexate—testicular cancer	0.000721	0.000721	CcSEcCtD
Ibandronate—Chills—Epirubicin—testicular cancer	0.000719	0.000719	CcSEcCtD
Ibandronate—Pruritus—Etoposide—testicular cancer	0.000719	0.000719	CcSEcCtD
Ibandronate—Alopecia—Epirubicin—testicular cancer	0.000708	0.000708	CcSEcCtD
Ibandronate—Vomiting—Cisplatin—testicular cancer	0.000705	0.000705	CcSEcCtD
Ibandronate—Mental disorder—Epirubicin—testicular cancer	0.000702	0.000702	CcSEcCtD
Ibandronate—Rash—Cisplatin—testicular cancer	0.000699	0.000699	CcSEcCtD
Ibandronate—Dermatitis—Cisplatin—testicular cancer	0.000698	0.000698	CcSEcCtD
Ibandronate—Malnutrition—Epirubicin—testicular cancer	0.000698	0.000698	CcSEcCtD
Ibandronate—Erythema—Epirubicin—testicular cancer	0.000698	0.000698	CcSEcCtD
Ibandronate—Diarrhoea—Etoposide—testicular cancer	0.000695	0.000695	CcSEcCtD
Ibandronate—Eye disorder—Doxorubicin—testicular cancer	0.000693	0.000693	CcSEcCtD
Ibandronate—Ill-defined disorder—Methotrexate—testicular cancer	0.000692	0.000692	CcSEcCtD
Ibandronate—Anaemia—Methotrexate—testicular cancer	0.000689	0.000689	CcSEcCtD
Ibandronate—Cardiac disorder—Doxorubicin—testicular cancer	0.000688	0.000688	CcSEcCtD
Ibandronate—Flatulence—Epirubicin—testicular cancer	0.000687	0.000687	CcSEcCtD
Ibandronate—Dysgeusia—Epirubicin—testicular cancer	0.000683	0.000683	CcSEcCtD
Ibandronate—Back pain—Epirubicin—testicular cancer	0.000675	0.000675	CcSEcCtD
Ibandronate—Angiopathy—Doxorubicin—testicular cancer	0.000673	0.000673	CcSEcCtD
Ibandronate—Malaise—Methotrexate—testicular cancer	0.000672	0.000672	CcSEcCtD
Ibandronate—Dizziness—Etoposide—testicular cancer	0.000672	0.000672	CcSEcCtD
Ibandronate—Muscle spasms—Epirubicin—testicular cancer	0.000671	0.000671	CcSEcCtD
Ibandronate—Immune system disorder—Doxorubicin—testicular cancer	0.00067	0.00067	CcSEcCtD
Ibandronate—Vertigo—Methotrexate—testicular cancer	0.00067	0.00067	CcSEcCtD
Ibandronate—Mediastinal disorder—Doxorubicin—testicular cancer	0.000668	0.000668	CcSEcCtD
Ibandronate—Chills—Doxorubicin—testicular cancer	0.000665	0.000665	CcSEcCtD
Ibandronate—Nausea—Cisplatin—testicular cancer	0.000659	0.000659	CcSEcCtD
Ibandronate—Alopecia—Doxorubicin—testicular cancer	0.000655	0.000655	CcSEcCtD
Ibandronate—Mental disorder—Doxorubicin—testicular cancer	0.00065	0.00065	CcSEcCtD
Ibandronate—Ill-defined disorder—Epirubicin—testicular cancer	0.000647	0.000647	CcSEcCtD
Ibandronate—Vomiting—Etoposide—testicular cancer	0.000646	0.000646	CcSEcCtD
Ibandronate—Malnutrition—Doxorubicin—testicular cancer	0.000646	0.000646	CcSEcCtD
Ibandronate—Erythema—Doxorubicin—testicular cancer	0.000646	0.000646	CcSEcCtD
Ibandronate—Anaemia—Epirubicin—testicular cancer	0.000645	0.000645	CcSEcCtD
Ibandronate—Rash—Etoposide—testicular cancer	0.00064	0.00064	CcSEcCtD
Ibandronate—Dermatitis—Etoposide—testicular cancer	0.00064	0.00064	CcSEcCtD
Ibandronate—Headache—Etoposide—testicular cancer	0.000636	0.000636	CcSEcCtD
Ibandronate—Flatulence—Doxorubicin—testicular cancer	0.000636	0.000636	CcSEcCtD
Ibandronate—Arthralgia—Methotrexate—testicular cancer	0.000635	0.000635	CcSEcCtD
Ibandronate—Chest pain—Methotrexate—testicular cancer	0.000635	0.000635	CcSEcCtD
Ibandronate—Myalgia—Methotrexate—testicular cancer	0.000635	0.000635	CcSEcCtD
Ibandronate—Dysgeusia—Doxorubicin—testicular cancer	0.000632	0.000632	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00063	0.00063	CcSEcCtD
Ibandronate—Malaise—Epirubicin—testicular cancer	0.000629	0.000629	CcSEcCtD
Ibandronate—Discomfort—Methotrexate—testicular cancer	0.000627	0.000627	CcSEcCtD
Ibandronate—Vertigo—Epirubicin—testicular cancer	0.000627	0.000627	CcSEcCtD
Ibandronate—Back pain—Doxorubicin—testicular cancer	0.000624	0.000624	CcSEcCtD
Ibandronate—Muscle spasms—Doxorubicin—testicular cancer	0.000621	0.000621	CcSEcCtD
Ibandronate—Palpitations—Epirubicin—testicular cancer	0.000617	0.000617	CcSEcCtD
Ibandronate—Anaphylactic shock—Methotrexate—testicular cancer	0.000608	0.000608	CcSEcCtD
Ibandronate—Infection—Methotrexate—testicular cancer	0.000604	0.000604	CcSEcCtD
Ibandronate—Nausea—Etoposide—testicular cancer	0.000603	0.000603	CcSEcCtD
Ibandronate—Hypertension—Epirubicin—testicular cancer	0.000602	0.000602	CcSEcCtD
Ibandronate—Ill-defined disorder—Doxorubicin—testicular cancer	0.000599	0.000599	CcSEcCtD
Ibandronate—Nervous system disorder—Methotrexate—testicular cancer	0.000597	0.000597	CcSEcCtD
Ibandronate—Anaemia—Doxorubicin—testicular cancer	0.000597	0.000597	CcSEcCtD
Ibandronate—Arthralgia—Epirubicin—testicular cancer	0.000594	0.000594	CcSEcCtD
Ibandronate—Chest pain—Epirubicin—testicular cancer	0.000594	0.000594	CcSEcCtD
Ibandronate—Myalgia—Epirubicin—testicular cancer	0.000594	0.000594	CcSEcCtD
Ibandronate—Anxiety—Epirubicin—testicular cancer	0.000592	0.000592	CcSEcCtD
Ibandronate—Skin disorder—Methotrexate—testicular cancer	0.000591	0.000591	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00059	0.00059	CcSEcCtD
Ibandronate—Hyperhidrosis—Methotrexate—testicular cancer	0.000588	0.000588	CcSEcCtD
Ibandronate—Discomfort—Epirubicin—testicular cancer	0.000587	0.000587	CcSEcCtD
Ibandronate—Malaise—Doxorubicin—testicular cancer	0.000582	0.000582	CcSEcCtD
Ibandronate—Dry mouth—Epirubicin—testicular cancer	0.000581	0.000581	CcSEcCtD
Ibandronate—Vertigo—Doxorubicin—testicular cancer	0.00058	0.00058	CcSEcCtD
Ibandronate—Palpitations—Doxorubicin—testicular cancer	0.00057	0.00057	CcSEcCtD
Ibandronate—Anaphylactic shock—Epirubicin—testicular cancer	0.000569	0.000569	CcSEcCtD
Ibandronate—Infection—Epirubicin—testicular cancer	0.000566	0.000566	CcSEcCtD
Ibandronate—Shock—Epirubicin—testicular cancer	0.00056	0.00056	CcSEcCtD
Ibandronate—Nervous system disorder—Epirubicin—testicular cancer	0.000558	0.000558	CcSEcCtD
Ibandronate—Hypertension—Doxorubicin—testicular cancer	0.000557	0.000557	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000554	0.000554	CcSEcCtD
Ibandronate—Skin disorder—Epirubicin—testicular cancer	0.000553	0.000553	CcSEcCtD
Ibandronate—Hyperhidrosis—Epirubicin—testicular cancer	0.00055	0.00055	CcSEcCtD
Ibandronate—Insomnia—Methotrexate—testicular cancer	0.00055	0.00055	CcSEcCtD
Ibandronate—Arthralgia—Doxorubicin—testicular cancer	0.00055	0.00055	CcSEcCtD
Ibandronate—Chest pain—Doxorubicin—testicular cancer	0.00055	0.00055	CcSEcCtD
Ibandronate—Myalgia—Doxorubicin—testicular cancer	0.00055	0.00055	CcSEcCtD
Ibandronate—Anxiety—Doxorubicin—testicular cancer	0.000548	0.000548	CcSEcCtD
Ibandronate—Paraesthesia—Methotrexate—testicular cancer	0.000546	0.000546	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000546	0.000546	CcSEcCtD
Ibandronate—Discomfort—Doxorubicin—testicular cancer	0.000543	0.000543	CcSEcCtD
Ibandronate—Dry mouth—Doxorubicin—testicular cancer	0.000537	0.000537	CcSEcCtD
Ibandronate—Dyspepsia—Methotrexate—testicular cancer	0.000536	0.000536	CcSEcCtD
Ibandronate—Decreased appetite—Methotrexate—testicular cancer	0.000529	0.000529	CcSEcCtD
Ibandronate—Anaphylactic shock—Doxorubicin—testicular cancer	0.000527	0.000527	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000525	0.000525	CcSEcCtD
Ibandronate—Fatigue—Methotrexate—testicular cancer	0.000525	0.000525	CcSEcCtD
Ibandronate—Infection—Doxorubicin—testicular cancer	0.000523	0.000523	CcSEcCtD
Ibandronate—Pain—Methotrexate—testicular cancer	0.00052	0.00052	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000519	0.000519	CcSEcCtD
Ibandronate—Shock—Doxorubicin—testicular cancer	0.000518	0.000518	CcSEcCtD
Ibandronate—Nervous system disorder—Doxorubicin—testicular cancer	0.000517	0.000517	CcSEcCtD
Ibandronate—Insomnia—Epirubicin—testicular cancer	0.000515	0.000515	CcSEcCtD
Ibandronate—Skin disorder—Doxorubicin—testicular cancer	0.000512	0.000512	CcSEcCtD
Ibandronate—Paraesthesia—Epirubicin—testicular cancer	0.000511	0.000511	CcSEcCtD
Ibandronate—Hyperhidrosis—Doxorubicin—testicular cancer	0.000509	0.000509	CcSEcCtD
Ibandronate—Feeling abnormal—Methotrexate—testicular cancer	0.000501	0.000501	CcSEcCtD
Ibandronate—Dyspepsia—Epirubicin—testicular cancer	0.000501	0.000501	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methotrexate—testicular cancer	0.000498	0.000498	CcSEcCtD
Ibandronate—Decreased appetite—Epirubicin—testicular cancer	0.000495	0.000495	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000492	0.000492	CcSEcCtD
Ibandronate—Fatigue—Epirubicin—testicular cancer	0.000491	0.000491	CcSEcCtD
Ibandronate—Pain—Epirubicin—testicular cancer	0.000487	0.000487	CcSEcCtD
Ibandronate—Constipation—Epirubicin—testicular cancer	0.000487	0.000487	CcSEcCtD
Ibandronate—Urticaria—Methotrexate—testicular cancer	0.000483	0.000483	CcSEcCtD
Ibandronate—Abdominal pain—Methotrexate—testicular cancer	0.000481	0.000481	CcSEcCtD
Ibandronate—Body temperature increased—Methotrexate—testicular cancer	0.000481	0.000481	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00048	0.00048	CcSEcCtD
Ibandronate—Insomnia—Doxorubicin—testicular cancer	0.000476	0.000476	CcSEcCtD
Ibandronate—Paraesthesia—Doxorubicin—testicular cancer	0.000473	0.000473	CcSEcCtD
Ibandronate—Feeling abnormal—Epirubicin—testicular cancer	0.000469	0.000469	CcSEcCtD
Ibandronate—Gastrointestinal pain—Epirubicin—testicular cancer	0.000466	0.000466	CcSEcCtD
Ibandronate—Dyspepsia—Doxorubicin—testicular cancer	0.000464	0.000464	CcSEcCtD
Ibandronate—Decreased appetite—Doxorubicin—testicular cancer	0.000458	0.000458	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000455	0.000455	CcSEcCtD
Ibandronate—Fatigue—Doxorubicin—testicular cancer	0.000454	0.000454	CcSEcCtD
Ibandronate—Urticaria—Epirubicin—testicular cancer	0.000452	0.000452	CcSEcCtD
Ibandronate—Pain—Doxorubicin—testicular cancer	0.000451	0.000451	CcSEcCtD
Ibandronate—Constipation—Doxorubicin—testicular cancer	0.000451	0.000451	CcSEcCtD
Ibandronate—Abdominal pain—Epirubicin—testicular cancer	0.00045	0.00045	CcSEcCtD
Ibandronate—Body temperature increased—Epirubicin—testicular cancer	0.00045	0.00045	CcSEcCtD
Ibandronate—Hypersensitivity—Methotrexate—testicular cancer	0.000448	0.000448	CcSEcCtD
Ibandronate—Asthenia—Methotrexate—testicular cancer	0.000437	0.000437	CcSEcCtD
Ibandronate—Feeling abnormal—Doxorubicin—testicular cancer	0.000434	0.000434	CcSEcCtD
Ibandronate—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000431	0.000431	CcSEcCtD
Ibandronate—Pruritus—Methotrexate—testicular cancer	0.00043	0.00043	CcSEcCtD
Ibandronate—Hypersensitivity—Epirubicin—testicular cancer	0.000419	0.000419	CcSEcCtD
Ibandronate—Urticaria—Doxorubicin—testicular cancer	0.000419	0.000419	CcSEcCtD
Ibandronate—Abdominal pain—Doxorubicin—testicular cancer	0.000416	0.000416	CcSEcCtD
Ibandronate—Body temperature increased—Doxorubicin—testicular cancer	0.000416	0.000416	CcSEcCtD
Ibandronate—Diarrhoea—Methotrexate—testicular cancer	0.000416	0.000416	CcSEcCtD
Ibandronate—Asthenia—Epirubicin—testicular cancer	0.000409	0.000409	CcSEcCtD
Ibandronate—Pruritus—Epirubicin—testicular cancer	0.000403	0.000403	CcSEcCtD
Ibandronate—Dizziness—Methotrexate—testicular cancer	0.000402	0.000402	CcSEcCtD
Ibandronate—Diarrhoea—Epirubicin—testicular cancer	0.00039	0.00039	CcSEcCtD
Ibandronate—Hypersensitivity—Doxorubicin—testicular cancer	0.000388	0.000388	CcSEcCtD
Ibandronate—Vomiting—Methotrexate—testicular cancer	0.000387	0.000387	CcSEcCtD
Ibandronate—Rash—Methotrexate—testicular cancer	0.000384	0.000384	CcSEcCtD
Ibandronate—Dermatitis—Methotrexate—testicular cancer	0.000383	0.000383	CcSEcCtD
Ibandronate—Headache—Methotrexate—testicular cancer	0.000381	0.000381	CcSEcCtD
Ibandronate—Asthenia—Doxorubicin—testicular cancer	0.000378	0.000378	CcSEcCtD
Ibandronate—Dizziness—Epirubicin—testicular cancer	0.000377	0.000377	CcSEcCtD
Ibandronate—Pruritus—Doxorubicin—testicular cancer	0.000373	0.000373	CcSEcCtD
Ibandronate—Vomiting—Epirubicin—testicular cancer	0.000362	0.000362	CcSEcCtD
Ibandronate—Nausea—Methotrexate—testicular cancer	0.000361	0.000361	CcSEcCtD
Ibandronate—Diarrhoea—Doxorubicin—testicular cancer	0.00036	0.00036	CcSEcCtD
Ibandronate—Rash—Epirubicin—testicular cancer	0.000359	0.000359	CcSEcCtD
Ibandronate—Dermatitis—Epirubicin—testicular cancer	0.000359	0.000359	CcSEcCtD
Ibandronate—Headache—Epirubicin—testicular cancer	0.000357	0.000357	CcSEcCtD
Ibandronate—Dizziness—Doxorubicin—testicular cancer	0.000348	0.000348	CcSEcCtD
Ibandronate—Nausea—Epirubicin—testicular cancer	0.000338	0.000338	CcSEcCtD
Ibandronate—Vomiting—Doxorubicin—testicular cancer	0.000335	0.000335	CcSEcCtD
Ibandronate—Rash—Doxorubicin—testicular cancer	0.000332	0.000332	CcSEcCtD
Ibandronate—Dermatitis—Doxorubicin—testicular cancer	0.000332	0.000332	CcSEcCtD
Ibandronate—Headache—Doxorubicin—testicular cancer	0.00033	0.00033	CcSEcCtD
Ibandronate—Nausea—Doxorubicin—testicular cancer	0.000313	0.000313	CcSEcCtD
